Answers are grounded in this paper and cite their sources.
Antimicrobial resistance (AMR) is responsible for an estimated 1.27 million deaths annually, driving urgent demand for novel therapeutics. Silver nanoparticles (AgNPs) have attracted significant interest due to their multi-target antibacterial activity, which presents a higher evolutionary barrier to resistance compared to conventional single-target antibiotics. However, AgNP monotherapy is limited by a narrow, formulation-dependent systemic therapeutic window, whereas repeated sublethal exposure may promote adaptive phenotypes. Combination with conventional antibiotics may enhance antimicrobial activity while reducing the concentrations of individual agents. This review examines the in vivo evidence for the efficacy of AgNPs against resistant pathogens, the physicochemical determinants governing their biological activity, and the translational barriers that limit clinical application. While in vivo literature provides preclinical evidence of antibacterial efficacy and potential synergistic activity of AgNP-antibiotic combinations, systemic infections caused by priority pathogens remain understudied. Consequently, four critical translational gaps are identified: 1) the absence of a pharmacokinetic/pharmacodynamic (PK/PD) dosing framework; 2) insufficient systemic infection models; 3) limited understanding of potential effects on polymicrobial communities; and 4) inconsistent physicochemical characterization limiting cross-study comparison. Addressing these gaps through integrated preclinical evaluation will be essential for determining whether AgNPs can serve as safe and effective adjuvants to existing antimicrobial therapies.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: